Ring Nitrogen Is Shared By The Cyclos Of The Bicyclo Ring System Patents (Class 514/413)
-
Patent number: 8519155Abstract: The present invention relates to the choline and tromethamine salt of Licofelone.Type: GrantFiled: October 30, 2009Date of Patent: August 27, 2013Assignee: c-a-i-r biosciences GmbHInventors: Wolfgang Albrecht, Hans-Günter Striegel, Stefan Laufer
-
Patent number: 8512717Abstract: The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.Type: GrantFiled: August 5, 2004Date of Patent: August 20, 2013Assignee: Allergan, Inc.Inventors: Joseph G. Vehige, James N. Chang, Richard Graham, Robert T. Lyons, Teresa H. Kuan, Chin-Ming Chang
-
Publication number: 20130209548Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: ApplicationFiled: March 6, 2013Publication date: August 15, 2013Applicant: PACIRA PHARMACEUTICALS, INC.Inventor: PACIRA PHARMACEUTICALS, INC.
-
Publication number: 20130209547Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: ApplicationFiled: March 6, 2013Publication date: August 15, 2013Applicant: PACIRA PHARMACEUTICALS INC.Inventor: PACIRA PHARMACEUTICALS INC
-
Publication number: 20130203833Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: ALLERGAN SALES, LLCInventor: Allergan Sales, LLC
-
Publication number: 20130203834Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: ALLERGAN SALES, LLCInventor: ALLERGAN SALES, LLC
-
Publication number: 20130197051Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: ALLERGAN SALES, LLCInventor: Allergan Sales, LLC
-
Publication number: 20130196973Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.Type: ApplicationFiled: March 13, 2012Publication date: August 1, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Asitha Abeywardane, Michael J. Burke, Thomas Martin Kirrane, Matthew Russell Netherton, Anil Kumar Padyana, Lana Louise Smith Keenan, Hidenori Takahashi, Michael Robert Turner, Qiang Zhang, Qing Zhang
-
Publication number: 20130189350Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: ApplicationFiled: March 8, 2013Publication date: July 25, 2013Applicant: PACIRA PHARMACEUTICALS, INC.Inventor: Pacira Pharmaceuticals, Inc.
-
Publication number: 20130189348Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: ApplicationFiled: March 6, 2013Publication date: July 25, 2013Applicant: PACIRA PHARMACEUTICALS, INC.Inventor: PACIRA PHARMACEUTICALS, INC.
-
Publication number: 20130183374Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: ApplicationFiled: March 6, 2013Publication date: July 18, 2013Applicant: PACIRA PHARMACEUTICALS, INC.Inventor: PACIRA PHARMACEUTICALS, INC.
-
Publication number: 20130157990Abstract: A method of detoxifying a patient addicted to at least one drug comprises the step of administering a first-medication component to the patient for mitigating drug withdrawal symptoms of the patient. The method further comprises the step of administering an anesthetic component to the patient for putting the patient in a sedated state. The method further comprises the step of administering a detoxification component to the patient for detoxifying the patient of the drug(s) while the patient is in the sedated state. The detoxification component can comprise naloxone. The method further comprises the step of administering a second-medication component to the patient for further mitigating drug withdrawal symptoms of the patient while the patient is in the sedated state. The second-medication component can comprise naltrexone. The method further comprises the step of terminating administration of the anesthetic component to the patient for reviving the patient from the sedated state.Type: ApplicationFiled: February 20, 2013Publication date: June 20, 2013Applicant: EAGLE ADVANCEMENT INSTITUTE LLCInventor: EAGLE ADVANCEMENT INSTITUTE LLC
-
Publication number: 20130157989Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.Type: ApplicationFiled: December 20, 2012Publication date: June 20, 2013Applicant: Theron Pharmaceuticals, Inc.Inventor: Theron Pharmaceuticals, Inc.
-
Publication number: 20130157963Abstract: Compositions and methods related to ophthalmic use of polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.Type: ApplicationFiled: December 14, 2012Publication date: June 20, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130137742Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: ApplicationFiled: January 14, 2013Publication date: May 30, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Patent number: 8445473Abstract: The invention relates to heteroaryl-substituted bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.Type: GrantFiled: April 13, 2009Date of Patent: May 21, 2013Assignee: The Regents of the University of MichiganInventors: Shaomeng Wang, Haiying Sun, Zaneta Nikolovska-Coleska
-
Publication number: 20130123285Abstract: The present invention provides an assay for screening any agent that modulates the ability of A3G to bind with RNA. The invention provides an agent identified by high throughput screening methods and methods of treatment using the identified agent as a means of inhibiting HIV infection and reducing the emergence of viral drug-resistance.Type: ApplicationFiled: May 13, 2011Publication date: May 16, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Harold C. Smith, Kimberly Prohaska, William M. McDougall
-
Publication number: 20130116232Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: June 8, 2011Publication date: May 9, 2013Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Nicholas D. Smith
-
Publication number: 20130065869Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.Type: ApplicationFiled: March 14, 2012Publication date: March 14, 2013Applicant: OMEROS CORPORATIONInventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
-
Publication number: 20130059898Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetyl-choline receptor-mediated diseases, such as pulmonary diseases, are provided.Type: ApplicationFiled: January 27, 2011Publication date: March 7, 2013Applicant: Theron Pharmaceuticals, Inc.Inventors: Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
-
Patent number: 8389561Abstract: This invention provides 1-substituted-7-azabicyclo[2.2.1]heptyl derivatives, intermediates and methods for producing them, which are therapeutic agents useful for the prevention and treatment of central nervous system disorders and diseases mediated by a Nicotinic Acetylcholine Receptor such as Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, pain, nicotine addiction and dementia.Type: GrantFiled: November 4, 2009Date of Patent: March 5, 2013Assignee: Universiteit GentInventors: Christian Stevens, Ann De Blieck, Thomas Heugebaert
-
Publication number: 20130045204Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, and wherein at least one of R1, R2, R3, R4 or R5 is F, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: August 17, 2012Publication date: February 21, 2013Applicants: The University of British Columbia, British Columbia Cancer Agency BranchInventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar, Carmen Adriana Banuelos, Nasrin Mawji, Jun Wang
-
Patent number: 8377982Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: GrantFiled: March 30, 2012Date of Patent: February 19, 2013Assignee: Allergan Sales, LLCInventors: Christopher A. Muller, Janet K. Cheetam, Teresa H. Kuan
-
Publication number: 20130030032Abstract: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.Type: ApplicationFiled: August 31, 2010Publication date: January 31, 2013Inventors: Eldon Q. Farnes, Mayssa Attar, Rhett M. Schiffman, Chin-Ming Chang, Richard S. Graham, Devin F. Welty
-
Publication number: 20120329850Abstract: Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.Type: ApplicationFiled: September 6, 2012Publication date: December 27, 2012Applicant: Allergan, Inc.Inventors: Scott M. Whitcup, David A. Weber
-
Publication number: 20120329849Abstract: This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation.Type: ApplicationFiled: September 4, 2012Publication date: December 27, 2012Inventors: Roger Whiting, Ramachandran Thirucote
-
Publication number: 20120322024Abstract: Provided herein is a strip, shaped for the application to the labile surface of the front teeth and/or gums of a subject, which strip is provided with at least one oral care composition for delivery to a pre-determined area of the teeth and/or gums of the subject. Also provided herein are uses for delivery of compositions. Further provided are uses of the strip in combination with a dental device.Type: ApplicationFiled: June 20, 2012Publication date: December 20, 2012Inventors: Guy De Vreese, Robin List
-
Patent number: 8334300Abstract: The present invention relates to novel C2-phenyl-substituted cyclic ketoenols of the formula (I) in which W, X, Y, Z and CKE are as defined in the description, to processes for their preparation and to their use as pesticides and herbicides.Type: GrantFiled: March 24, 2011Date of Patent: December 18, 2012Assignee: Bayer AktiengesellshaftInventors: Michael Ruther, Hermann Hagemann, Udo Schneider, Markus Dollinger, Peter Dahmen, Ulrike Wachendorff-Neumann, Reiner Fischer, Alan Graff, Thomas Bretschneider, Christophe Erdelen, Mark Wilhelm Drewes, Dieter Feucht, Folker Lieb
-
Publication number: 20120263779Abstract: A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics.Type: ApplicationFiled: June 13, 2012Publication date: October 18, 2012Inventors: Robert T. Lyons, James A. Burke, Michael R. Robinson
-
Publication number: 20120230972Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: May 22, 2012Publication date: September 13, 2012Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Publication number: 20120202780Abstract: A carrier composition of the present invention comprises a phosphate compound of an electron transfer agent and a relatively high concentration of a polar protic solvent. A biologically active compound may be formulated with a carrier composition of the present invention to provide a formulation.Type: ApplicationFiled: December 22, 2010Publication date: August 9, 2012Inventors: Paul David Gavin, Mahmoud El-Tamimy, Jeremy James Cottrell, Giacinto Gaetano, Nicholas John Kennedy
-
Publication number: 20120196913Abstract: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.Type: ApplicationFiled: April 13, 2012Publication date: August 2, 2012Applicant: ALLERGAN, INC.Inventors: Eldon Q. Farnes, Mayssa Attar, Rhett M. Schiffman, Chin-Ming Chang, Richard S. Graham, Devin F. Welty
-
Publication number: 20120196914Abstract: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.Type: ApplicationFiled: April 13, 2012Publication date: August 2, 2012Applicant: ALLERGAN, INC.Inventors: Eldon Quinn Farnes, Mayssa Attar, Rhett M. Schiffman, Chin-Ming Chang, Richard S. Graham, Devin F. Welty
-
Publication number: 20120190722Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: ApplicationFiled: March 30, 2012Publication date: July 26, 2012Applicant: ALLERGAN, INC.Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan
-
Patent number: 8207215Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: GrantFiled: October 17, 2007Date of Patent: June 26, 2012Assignee: Allergan, Inc.Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
-
Publication number: 20120156244Abstract: Pharmaceutical compositions for the treatment of nasal congestion, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective ?-2 adrenergic receptor agonists. Methods of using the compositions for the treatment of nasal congestion, cerebrovascular disease or systemic conditions, and as delivery vehicles to deliver other active agents to treat systemic or cerebrovascular diseases or conditions.Type: ApplicationFiled: February 27, 2012Publication date: June 21, 2012Applicant: ALPHA SYNERGY DEVELOPMENT INC.Inventor: Gerald Horn
-
Patent number: 8183277Abstract: Inhibitors of HCV replication of formula (I) wherein W is a heterocycle of formula and the remaining variables are as defined in the specification.Type: GrantFiled: July 28, 2006Date of Patent: May 22, 2012Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Dominique Louis Nestor Ghislain Surleraux, Wim Van De Vreken
-
Patent number: 8178535Abstract: Substituted sulfonamide compounds corresponding to the formula I? wherein m, n, p, X, Y, Z, R1, RA and RB have specified meanings, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these substituted sulfonamide compounds for the treatment and/or inhibition of pain or other conditions.Type: GrantFiled: January 16, 2009Date of Patent: May 15, 2012Assignee: Gruenenthal GmbHInventors: Beatrix Merla, Stefan Oberboersch, Ruth Jostock, Michael Engels, Stefan Schunk, Melanie Reich, Sabine Hees
-
Publication number: 20120114605Abstract: Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5-lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the present invention. In some embodiments, two or more 5-LO inhibitors are administered to a subject to treat a myeloproliferative disorder. In further embodiments, at least one 5-LO inhibitor and at least one additional therapeutic agent are administered to a subject to treat a myeloproliferative disorder. Methods of inhibiting leukemia stem cells are provided according to embodiments of the present invention which include contacting leukemia stem cells with an effective amount of an arachidonate 5-lipoxygenase inhibitor.Type: ApplicationFiled: April 26, 2010Publication date: May 10, 2012Inventor: Shaoguang Li
-
Publication number: 20120114740Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: ApplicationFiled: October 27, 2011Publication date: May 10, 2012Applicant: PACIRA PHARMACEUTICALS, INCInventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
-
Publication number: 20120101142Abstract: Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising: an aqueous solution comprising ketorolac or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg/mL to about 10 mg/mL; and a pharmaceutically acceptable excipient; wherein the formulation is substantially free of alcohol.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: RTU PHARMACEUTICALS, LLCInventors: Joseph V. Pergolizzi, Alexander Mironov, Chad James Pickens, Douglas Giles Johnson
-
Patent number: 8163793Abstract: The invention relates to a compound of formula (I) wherein A, R1-R6 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: GrantFiled: April 16, 2010Date of Patent: April 24, 2012Assignee: Hoffman-La Roche Inc.Inventors: Rubén Alvarez Sánchez, David Banner, Simona M. Ceccarelli, Uwe Grether, Wolfgang Haap, Peter Hartman, Guido Hartmann, Hans Hilpert, Holger Kuehne, Harald Mauser, Jean-Marc Plancher
-
Publication number: 20120094995Abstract: This invention relates to 2-aza-bicyclo[2.2.1]heptane compounds (and salts thereof), the process for making such a compound and pharmaceutical compositions comprising such a compound. The invention also relates to the use of the compounds for modulating the glycine transporter 1 (GlyT1) and for the treatment of psychosis, cognitive disorders, bipolar disorders, depression disorders, anxiety disorders, post-traumatic stress disorders and pain.Type: ApplicationFiled: January 27, 2010Publication date: April 19, 2012Applicant: ASTRAZENECA ABInventors: Jeffrey Scott Albert, Donald Andisik, Cristobal Alhambra, Todd Andrew Brugel, Glen E Ernst, William Frietze, Lindsay Hinkley, Jeffrey Gilbert Varnes, Xia Wang, Hui Xiong
-
Patent number: 8148416Abstract: A pharmaceutical composition and a method of treating inflammation in a mammal. The method administers the therapeutic composition to the mammal. The therapeutic composition includes: a standard therapeutic dose of a COX2 inhibitor consisting of celecoxib or rofecoxib; and low dose aspirin in an amount of 70-85 mg.Type: GrantFiled: January 21, 2008Date of Patent: April 3, 2012Inventors: Mawaheb M. El-Naggar, Ahmed S. Mousa
-
Publication number: 20120029044Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.Type: ApplicationFiled: January 27, 2011Publication date: February 2, 2012Inventors: Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
-
Publication number: 20120022001Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.Type: ApplicationFiled: September 12, 2011Publication date: January 26, 2012Applicant: STABLE SOLUTIONS LLCInventor: David F. Driscoll
-
Publication number: 20120015807Abstract: The present invention relates to novel trifluoromethoxyphenyl-substituted tetramic acid derivatives of the formula (I), in which J, X, Y, A, B, D and G have the meanings given above, to a number of processes for their preparation, and to their use as pesticides and/or herbicides. The invention further provides selective herbicidal compositions which comprise, firstly, trifluoromethoxyphenyl-substituted tetramic acid derivatives and, secondly, a crop plant compatibility-improving compound. The invention further relates to the boosting of the action of crop protection compositions comprising compounds of the formula (I) through the additions of ammonium salts or phosphonium salts and optionally penetrants.Type: ApplicationFiled: October 13, 2007Publication date: January 19, 2012Applicant: Bayer CropScience AGInventors: Reiner Fischer, Stefan Lehr, Christian Arnold, Thomas Auler, Jan Dittgen, Dieter Feucht, Eva-Maria Franken, Waltraud Hempel, Martin Jeffrey Hills, Heinz Kehne, Peter Losel, Olga Malsam, Christopher Hugh Rosinger, Erich Sanwald, Ulrich Gorgens, Stefan Antons, Wolfgang Ebenbeck, Axel Pleschke, Marielouise Schneider, Ralf Wischnat
-
Publication number: 20120010235Abstract: Compounds of formula and enantiomers and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control, amelioration or prevention of cancer.Type: ApplicationFiled: June 30, 2011Publication date: January 12, 2012Inventors: Xin-Jie Chu, Qingjie Ding, Nan Jiang, Jin-Jun Liu, Tina Morgan Ross, Zhuming Zhang
-
Publication number: 20120010261Abstract: The present invention relates to the choline and tromethamine salt of Licofelone.Type: ApplicationFiled: October 30, 2009Publication date: January 12, 2012Applicant: c-a-i-r biosciences GmbHInventors: Wolfgang Albrecht, Hans-Günter Striegel, Stefan Laufer
-
Patent number: RE43390Abstract: The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.Type: GrantFiled: October 27, 1998Date of Patent: May 15, 2012Assignees: GlaxoSmithKline LLC, SmithKline Beecham LimitedInventors: Valerie Joan Berry, Steven Dabbs, Colin Henry Frydrych, Eric Hunt, Francis Dominic Sanderson, Gary Woodnutt